Patient-Derived Tumor Organoid Rings for Histologic Characterization and High-Throughput Screening
Open accessAbstract
Tumor organoids are promising tools for cancer biology investigations and preclinical drug screenings because they are often representative of the histology and drug responses of patients. Here, we introduce a facile protocol to overcome technical limitations by generating patient-derived tumor organoids using a simplified ring-like geometry. This facilitates media exchange and drug treatment for histopathology characterization and automated high-throughput drug screenings. For complete details on the use and execution of this protocol, please refer to Phan et al. (2019).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
During malignant transformation, tumor cells gradually lose dependence on factors required for normal organoid growth.
“as tumor cells gradually lose dependence on those factors during malignant transformation59.”
From Organoids (2022) · cites this paper as [59]
The Organoid Culture Medium section lists supplements used to grow tumor organoids, but does not compare their requirements with normal organoids. Searches for loss of growth-factor dependence and malignant transformation found no passage addressing that claim. (LLM, conf=0.74)
Experimental — accuracy not yet measuredColorectal tumor organoids established from microsatellite instable tumors had higher de novo mutations after long-term culture than stable ones.
“Colorectal tumor organoids established from microsatellite instable tumors had higher de novo mutations after long-term culture than stable ones59.”
From Organoids (2022) · cites this paper as [59]
The Abstract describes a protocol for preparing tumor-organoid rings, and Expected Outcomes discusses ring quality and viability; neither reports a mutation comparison. Searches for microsatellite instability, de novo mutations, and long-term culture found no passage in our copy addressing the claimed difference between colorectal tumor organoids. (LLM, conf=0.76)
Experimental — accuracy not yet measuredIn colorectal cancer, benign tumor organoids showed no or minimal engraftment in mice, while colorectal cancer organoids derived from metastases were more invasive than those from primary tumors.
“In a study of colorectal cancer, benign tumor organoids showed no or minimal engraftment in mice. In contrast, colorectal cancer organoids derived from metastases were more invasive than those from primary tumors59.”
From Organoids (2022) · cites this paper as [59]
The Abstract (page unavailable) describes a protocol for tumor-organoid rings, and Expected Outcomes (page unavailable) discusses ring preparation and cell viability. Searches for engraftment of benign colorectal organoids in mice and invasiveness of metastasis-derived versus primary-tumor organoids found no passage addressing either comparison. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 1 · Cited by 36
- Authors
- Nguyen, H. T. L., & Soragni, A.
- Affiliations
- University of California, Los Angeles (US)
- California NanoSystems Institute (US)
- Corresponding author
- Soragni, Alice
- Venue
- STAR Protocols
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 1
- Issue
- 2
- Pages
- 100056
- ISSN
- 2666-1667 (ISSN-L)
- PMC
- PMC7546514
- OpenAlex
- W3037344278
- Cited by
- 36
- References
- 1
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 6 · 2023: 2 · 2022: 7 · 2021: 2 · 2020: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- STAR Protocols (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Worldwide Cancer Research
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- patient-derived tumor organoids, high-throughput drug screening, preclinical drug screening, tumor histology
- MeSH terms
- Histocytochemistry, Humans, Neoplasms, Organoids, Tumor Cells, Cultured, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
